|
| Targeting leukemia stem cells: in vitro veritas |
|
https://doi.org/10.18632/oncotarget.1777
Heather M. Bond, Maria Mesuraca, and Giovanni Morrone
|
| 575-576 |
|
| Ras and autophagy in cancer development and therapy |
|
https://doi.org/10.18632/oncotarget.1775
Eran Schmukler, Yoel Kloog, and Ronit Pinkas-Kramarski
|
| 577-586 |
|
| Immune regulation by low doses of the DNA methyltransferase inhibitor 5azacitidine in common human epithelial cancers |
|
https://doi.org/10.18632/oncotarget.1782
Huili Li, Katherine B. Chiappinelli, Angela A. Guzzetta, Hariharan Easwaran, Ray-Whay Chiu Yen, Rajita Vatapalli, Michael J. Topper, Jianjun Luo, Roisin M. Connolly, Nilofer S. Azad, Vered Stearns, Drew M. Pardoll, Nancy Davidson, Peter A. Jones, Dennis J. Slamon, Stephen B. Baylin, Cynthia A. Zahnow, and Nita Ahuja
|
| 587-598 |
|
| A differential role for CXCR4 in the regulation of normal versus malignant breast stem cell activity |
|
https://doi.org/10.18632/oncotarget.1169
Matthew P Ablett, Ciara S O'Brien, Andrew H Sims, Gillian Farnie, and Robert B Clarke
|
| 599-612 |
|
| Adiposederived mesenchymal stem cells ASCs may favour breast cancer recurrence via HGF/cMet signaling |
|
https://doi.org/10.18632/oncotarget.1359
Vincenzo Eterno, Alberto Zambelli, Lorenzo Pavesi, Laura Villani, Vittorio Zanini, Gianfranco Petrolo, Stefania Manera, Antonella Tuscano, and Angela Amato
|
| 613-633 |
|
| Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NFκB regulated gene products in multiple myeloma xenograft mouse model |
|
https://doi.org/10.18632/oncotarget.1596
Kodappully Sivaraman Siveen, Nurulhuda Mustafa, Feng Li, Radhamani Kannaiyan, Kwang Seok Ahn, Alan Prem Kumar, Wee-Joo Chng, and Gautam Sethi
|
| 634-648 |
|
| Lymphoid enhancer binding factor1 LEF1 expression as a prognostic factor in adult acute promyelocytic leukemia |
|
https://doi.org/10.18632/oncotarget.1619
Francesco Albano, Antonella Zagaria, Luisa Anelli, Paola Orsini, Crescenzio F Minervini, Luciana Impera, Paola Casieri, Nicoletta Coccaro, Giuseppina Tota, Claudia Brunetti, Angela Minervini, Domenico Pastore, Paola Carluccio, Anna Mestice, Angelo Cellamare, and Giorgina Specchia
|
| 649-658 |
|
| Large scale integration of drugtarget information reveals polypharmacological drug action mechanisms in tumor cell line growth inhibition assays |
|
https://doi.org/10.18632/oncotarget.1597
Richard Knight, Mikhail Gostev, Sergei Ilisavskii, Anne E Willis, Gerry Melino, and Alexey V Antonov
|
| 659-666 |
|
| Targeting CDC25C PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer |
|
https://doi.org/10.18632/oncotarget.1574
Nader Al Nakouzi, Sophie Cotteret, Frédéric Commo, Catherine Gaudin, Shanna Rajpar, Philippe Dessen, Philippe Vielh, Karim Fizazi, and Anne Chauchereau
|
| 667-678 |
|
| Pcadherin signals through the laminin receptor α6β4 integrin to induce stem cell and invasive properties in basallike breast cancer cells |
|
https://doi.org/10.18632/oncotarget.1459
André Filipe Vieira, Ana Sofia Ribeiro, Maria Rita DionÃsio, Bárbara Sousa, Ana Nobre, André Albergaria, Angélica Santiago-Gómez, Nuno Mendes, Renê Gerhard, Fernando Schmitt, Robert Brian Clarke, and Joana Paredes
|
| 679-692 |
|
| AKT mediates actinomycin Dinduced p53 expression |
|
https://doi.org/10.18632/oncotarget.1328
Chih-Shou Chen, Dong-Ru Ho, Fei-Yun Chen, Chang-Rong Chen, Yu-De Ke, and Jyan-Gwo J Su
|
| 693-703 |
|
| Immunogenicity of targeted lentivectors |
|
https://doi.org/10.18632/oncotarget.1680
Cleo Goyvaerts, De Groeve Kurt, Sandra Van Lint, Carlo Heirman, Jo A. Van Ginderachter, Patrick De Baetselier, Geert Raes, Kris Thielemans, and Karine Breckpot
|
| 704-715 |
|
| Cytotoxic effects of 15dPGJ2 against osteosarcoma through ROSmediated AKT and cell cycle inhibition |
|
https://doi.org/10.18632/oncotarget.1704
Chueh-Chuan Yen, Chung-Der Hsiao, Wei-Ming Chen, Yao-Shan Wen, Yung-Chan Lin, Ting-Wei Chang, Fang-Yi Yao, Shih-Chieh Hung, Jir-You Wang, Jen-Hwey Chiu, Hsei-Wei Wang, Chi-Hung Lin, Tain-Hsiung Chen, Paul Chih-Hsueh Chen, Chien-Lin Liu, Cheng-Hwai Tzeng, and Jonathan A. Fletcher
|
| 716-725 |
|
| Synergistic antitumor activity of acadesine AICAR in combination with the antiCD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma |
|
https://doi.org/10.18632/oncotarget.1455
Arnau Montraveta, Silvia Xargay-Torrent, Mónica López-Guerra, Laia Rosich, Patricia Pérez-Galán, Itziar Salaverria, Silvia Beà , Susana G. Kalko, Mercè de Frias, Clara Campà s, Gaël Roué, and Dolors Colomer
|
| 726-739 |
|
| Sp1mediated microRNA182 expression regulates lung cancer progression |
|
https://doi.org/10.18632/oncotarget.1608
Wen-Bin Yang, Ping-Hsin Chen, Tsung-I Hsu, Tzu-Fun Fu, Wu-Chou Su, Hungjiun Liaw, Wen-Chang Chang, and Jan-Jong Hung
|
| 740-753 |
|
| MUC1C nuclear localization drives invasiveness of renal cancer cells through a sheddase/gamma secretase dependent pathway |
|
https://doi.org/10.18632/oncotarget.1768
Audrey Bouillez, Viviane Gnemmi, Kelly Gaudelot, Brigitte Hémon, Bélinda Ringot, Nicolas Pottier, François Glowacki, Caroline Butruille, Christelle Cauffiez, Malika Hamdane, Nicolas Sergeant, Isabelle Van Seuningen, Xavier Leroy, Sébastien Aubert, and Michaël Perrais
|
| 754-763 |
|
| Identification of a long noncoding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer |
|
https://doi.org/10.18632/oncotarget.1769
Francesco Crea, Akira Watahiki, Luca Quagliata, Hui Xue, Larissa Pikor, Abhijit Parolia, Yuwei Wang, Dong Lin, Wan L. Lam, William L. Farrar, Takao Isogai, Rudolf Morant, Serenella Castori-Eppenberger, Kim N. Chi, Yuzhuo Wang, and Cheryl D. Helgason
|
| 764-774 |
|
| Targeting Srcmediated Tyr216 phosphorylation and activation of GSK3 in prostate cancer cells inhibit prostate cancer progression in vitro and in vivo |
|
https://doi.org/10.18632/oncotarget.1770
Anna Goc, Belal Al-Husein Al-Husein, Katerina Katsanevas, Alison Steinbach, Uvette Lou, Harika Sabbineni, David L. DeRemer, and Payaningal R. Somanath
|
| 775-787 |
|
| LIF promotes tumorigenesis and metastasis of breast cancer through the AKTmTOR pathway |
|
https://doi.org/10.18632/oncotarget.1772
Xiaoyan Li, Qifeng Yang, Haiyang Yu, Lihua Wu, Yuhan Zhao, Cen Zhang, Xuetian Yue, Zhen Liu, Hao Wu, Bruce G. Haffty, Zhaohui Feng, and Wenwei Hu
|
| 788-801 |
|
| Tolllike receptor5 agonist Entolimod broadens the therapeutic window of 5fluorouracil by reducing its toxicity to normal tissues in mice |
|
https://doi.org/10.18632/oncotarget.1773
Bojidar M. Kojouharov, Craig M. Brackett, Jean M. Veith, Christopher P. Johnson, Ilya I. Gitlin, Ilia A. Toshkov, Anatoli S. Gleiberman, Andrei V. Gudkov, and Lyudmila G. Burdelya
|
| 802-814 |
|
| PHLPP2 suppresses the NFκB pathway by inactivating IKKβ kinase |
|
https://doi.org/10.18632/oncotarget.1774
Nitin Kumar Agarwal, Xiaoping Zhu, Mihai Gagea, Charles L. White, Gilbert Cote, and Maria-Magdalena Georgescu
|
| 815-823 |
|
| Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients |
|
https://doi.org/10.18632/oncotarget.1776
Prashant K. Singh, Leah Preus, Qiang Hu, Li Yan, Mark D. Long, Carl D. Morrison, Mary Nesline, Candace S. Johnson, Shahriar Koochekpour, Manish Kohli, Song Liu, Donald L. Trump, Lara E. Sucheston-Campbell, and Moray J. Campbell
|
| 824-840 |
|
| Hydrogen peroxide/ATRChk2 activation mediates p53 protein stabilization and anticancer activity of cheliensisin A in human cancer cells |
|
https://doi.org/10.18632/oncotarget.1780
Jingjie Zhang, Guangxun Gao, Liang Chen, Jingxia Li, Xu Deng, Qin-shi Zhao, and Chuanshu Huang
|
| 841-852 |
|
| Frequent L1 retrotranspositions originating from TTC28 in colorectal cancer |
|
https://doi.org/10.18632/oncotarget.1781
Esa Pitkänen, Tatiana Cajuso, Riku Katainen, Eevi Kaasinen, Niko Välimäki, Kimmo Palin, Jussi Taipale, Lauri A. Aaltonen, and Outi Kilpivaara
|
| 853-859 |
